Wir nutzen Cookies auf unserer Website. Einige von ihnen sind essenziell, während andere uns helfen, diese Website und Ihre Erfahrung zu verbessern.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Speichert die aktuelle PHP-Session.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Inhalte von Drittanbietern, bspw. Aktienwidgets, werden standardmäßig blockiert. Wenn Cookies von Drittanbietern akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Einwilligung mehr.
Wir verwenden zur Aktien-Chart-Anzeige den Anbieter TradingView. Dieser setzt weitere Cookies zur Analyse seiner Dienste ein.
Sie können unseren Newsletter abonnieren, dazu nutzen wir die Dienste von EQS. Dieser Anbieter setzt bei der Registrierung selbst verschiedene Cookies zur Nutzungsanalyse seiner Dienste ein.
Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of …
In the first nine months of the 2023 financial year, preliminary IFRS consolidated sales rose by around 13% to EUR 212.2 million compared to the same period in 2022 (EUR 188.2 million). The result from ordinary activities (EBITDA) increased strongly by around 33% from EUR 7.7 million to EUR 10.2 million. The operating result (EBIT) even increased …
Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out. After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to …
HAEMATO AG has continued its profitable growth course in the new year and increased its revenue in the first half of 2023 by EUR 12.7 million compared to the same period in 2022 to EUR 133.64 million. This represents a growth in turnover of 10.5 % compared to the same period of the previous year.
HAEMATO AG has continued its profitable growth course in the new year and increased its revenue in the first quarter of 2023 by EUR 13.8 million compared to the same quarter of 2022 to EUR 68.4 million. This represents a growth in turnover of 25.3 % compared to the same period of the previous year.
At today's balance sheet meeting, the annual financial statements 2022 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.20 per dividend-bearing share to the Annual General Meeting taking place …